

V. Literaturnachweis

1. U.-N.Riede, H.-E.Schaefer. Allgemeine und spezielle Pathologie. Georg Thieme Verlag, 1995.
2. Schwameis E, Abdolvahab F, Wurnig C. ⁵. Radiologe 36:823-833, 1996.
3. Waldvogel FA, Papageorgiou PS. Osteomyelitis: the past decade. N Engl J Med 303:360-370, 1980.
4. Kahn DS, Pritzker KP. The pathophysiology of bone infection. Clin Orthop 96:12-19, 1973.
5. Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med 282:198-206, 1970.
6. Wening JV, Stein M, Langendorff U, Delling G. [Chronic osteomyelitis and cancer of the fistula]. Langenbecks Arch Chir 374:55-59, 1989.
7. Look P, Kleinau W, Henze E. [Fistula carcinoma arising from chronic osteomyelitis (author's transl)]. Zentralbl Chir 102:998-1005, 1977.
8. Dranert K, Ruter A, Burri C, Willenegger H. [Malignant degeneration of fistulas in chronic osteomyelitis (author's transl)]. Arch Orthop Unfallchir 84:199-210, 1976.
9. Alabi ZO, Ojo OS, Odesanmi WO. Secondary amyloidosis in chronic osteomyelitis. Int Orthop 15:21-22, 1991.
10. Kuhlback B, Falck H, Tornroth T, Wallenius M, Lindstrom BL, Pasternack A. Renal transplantation in amyloidosis. Acta Med Scand 205:169-172, 1979.

11. Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. *Medicine Baltimore* 54:271-299, 1975.
12. Eron LJ. Prevention of infection following orthopedic surgery. *Antibiot Chemother* 33:140-164, 1985.
13. Cheatle MD. The effect of chronic orthopedic infection on quality of life. *Orthop Clin North Am* 22:539-547, 1991.
14. Carek PJ, Dickerson LM, Sack JL. Diagnosis and management of osteomyelitis. *Am Fam Physician* 63:2413-2420, 2001.
15. Carlson DA, Dobozi WR. Hematogenous *Salmonella typhi* osteomyelitis of the radius. A case report. *Clin Orthop* 187-191, 1994.
16. Sarria JC, Vidal AM, Kimbrough RC. *Haemophilus influenzae* osteomyelitis in adults: a report of 4 frontal bone infections and a review of the literature. *Scand J Infect Dis* 33:263-265, 2001.
17. Stratov I, Korman TM, Johnson PD. Management of *Aspergillus* osteomyelitis: report of failure of liposomal amphotericin B and response to voriconazole in an immunocompetent host and literature review. *Eur J Clin Microbiol Infect Dis* 22:277-283, 2003.
18. El Zaatari MM et al. Successful treatment of *Candida albicans* osteomyelitis of the spine with fluconazole and surgical debridement: case report. *J Chemother* 14:627-630, 2002.
19. Kelly PJ, Martin WJ, Coventry MB. Chronic osteomyelitis. II. Treatment with closed irrigation and suction. *JAMA* 213:1843-1848, 1970.
20. May J-WJ, Jupiter JB, Weiland AJ, Byrd HS. Clinical classification of post-traumatic tibial osteomyelitis. *J Bone Joint Surg Am* 71:1422-1428, 1989.

21. Weiland AJ, Moore JR, Daniel RK. The efficacy of free tissue transfer in the treatment of osteomyelitis. *J Bone Joint Surg Am* 66:181-193, 1984.
22. Cierny G, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. *Clin Orthop* 7-24, 2003.
23. Periti P, Mini E, Mosconi G. Antimicrobial prophylaxis in orthopaedic surgery: the role of teicoplanin [see comments] [published errata appear in *J Antimicrob Chemother* 1998 Nov;42(5):682 and 1998 Dec;42(6):840]. *J Antimicrob Chemother* 41:329-340, 1998.
24. Court BC. Antibiotic prophylaxis in orthopaedic surgery. *Scand J Infect Dis Suppl* 70:74-79, 1990.
25. Taylor GJ, Bannister GC, Calder S. Perioperative wound infection in elective orthopaedic surgery [published erratum appears in *J Hosp Infect* 1991 Feb;17(2):155]. *J Hosp Infect* 16:241-247, 1990.
26. Sanderson PJ. Preventing infection in orthopaedic implants. *J Antimicrob Chemother* 24:277-280, 1989.
27. Petty W, Spanier S, Shuster JJ, Silverthorne C. The influence of skeletal implants on incidence of infection. Experiments in a canine model. *J Bone Joint Surg Am* 67:1236-1244, 1985.
28. Ostermann PA, Henry SL, Seligson D.²⁸ *Langenbecks Arch Chir* 378:32-36, 1993.
29. Seligson D, Klemm K. Adult posttraumatic osteomyelitis of the tibial diaphysis of the tibial shaft. *Clin Orthop* 30-36, 1999.
30. Bencini PL, Galimberti M, Signorini M, Crosti C. Antibiotic prophylaxis of wound infections in skin surgery. *Arch Dermatol* 127:1357-1360, 1991.

31. Tsukayama DT. Pathophysiology of posttraumatic osteomyelitis. *Clin Orthop* 22-29, 1999.
32. Bauer TW, Schils J. The pathology of total joint arthroplasty. II. Mechanisms of implant failure. *Skeletal Radiol* 28:483-497, 1999.
33. Heiss F., Hahn F. Hämatogene Spätinfektion einer Kniegelenktotalendoprothese. 1990. Das infizierte Implantat / 7. Steglitzer Unfalltagung, Springer Verlag.
Ref Type: Conference Proceeding
34. Tunney MM et al. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. *J Clin Microbiol* 37:3281-3290, 1999.
35. Melcher GA, Metzdorf A, Schlegel U, Ziegler WJ, perren SM, Printzen G. Influence of reaming versus nonreaming in intramedullary nailing on local infection rate: experimental investigation in rabbits. *J Trauma* 39:1123-1128, 1995.
36. Melcher GA, Claudi B, Schlegel U, perren SM, Printzen G, Munzinger J. Influence of type of medullary nail on the development of local infection. An experimental study of solid and slotted nails in rabbits. *J Bone Joint Surg Br* 76:955-959, 1994.
37. Sanzen L, Linder L. Infection adjacent to titanium and bone cement implants: an experimental study in rabbits. *Biomaterials* 16:1273-1277, 1995.
38. Gristina AG, Oga M, Webb LX, Hobgood CD. Adherent bacterial colonization in the pathogenesis of osteomyelitis. *Science* 228:990-993, 1985.
39. Gristina AG, Costerton JW. Bacterial adherence to biomaterials and tissue. The significance of its role in clinical sepsis. *J Bone Joint Surg Am* 67:264-273, 1985.

40. Holtom PD, Smith AM. Introduction to adult posttraumatic osteomyelitis of the tibia. *Clin Orthop* 6-13, 1999.
41. Leach WJ, Wilson NI. Trends in infection prophylaxis in orthopaedics. *J R Coll Surg Edinb* 37:265-266, 1992.
42. Finegold SM. Host factors predisposing to anaerobic infection. *FEMS Immunol Med Microbiol* 6:159-163, 1993.
43. Andrikos E. et al. Effect of daily hemodialysis on monocytes apoptosis. *Blood Purif* 23:79-82, 2005.
44. Herrmann M et al. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material. *J Infect Dis* 158:693-701, 1988.
45. Ryden C et al. Specific binding of bone sialoprotein to *Staphylococcus aureus* isolated from patients with osteomyelitis. *Eur J Biochem* 184:331-336, 1989.
46. Buxton TB et al. Binding of a *Staphylococcus aureus* bone pathogen to type I collagen. *Microb Pathog* 8:441-448, 1990.
47. Meghji S, Henderson B, Nair S, Wilson M. Inhibition of bone DNA and collagen production by surface-associated material from bacteria implicated in the pathology of periodontal disease. *J Periodontol* 63:736-742, 1992.
48. Nair S et al. Surface-associated proteins from *Staphylococcus aureus* demonstrate potent bone resorbing activity. *J Bone Miner Res* 10:726-734, 1995.
49. Meghji S, Wilson M, Henderson B, Kinane D. Anti-proliferative and cytotoxic activity of surface-associated material from periodontopathogenic bacteria. *Arch Oral Biol* 37:637-644, 1992.

50. König B, Prevost G, Piemont Y, König W. Effects of *Staphylococcus aureus* leukocidins on inflammatory mediator release from human granulocytes. *J Infect Dis* 171:607-613, 1995.
51. Sterrett JD. The osteoclast and periodontitis. *J Clin Periodontol* 13:258-269, 1986.
52. de la Mata J et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. *J Clin Invest* 95:2846-2852, 1995.
53. Puzas JE, Hicks DG, Reynolds SD, O'Keefe RJ. Regulation of osteoclastic activity in infection. *Methods Enzymol* 236:47-58, 1994.
54. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. *Nature* 322:547-549, 1986.
55. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. *Nature* 319:516-518, 1986.
56. Charnley J, Eftekhar N. Postoperative infection in total prosthetic replacement arthroplasty of the hip-joint. With special reference to the bacterial content of the air of the operating room. *Br J Surg* 56:641-649, 1969.
57. Charnley J. Postoperative infection after total hip replacement with special reference to air contamination in the operating room. *Clin Orthop* 87:167-187, 1972.
58. Lidwell OM, Lowbury EJ, Whyte W, Blowers R, Stanley SJ, Lowe D. Effect of ultraclean air in operating rooms on deep sepsis in the joint after total hip or knee replacement: a randomised study. *Br Med J (Clin Res Ed)* 285:10-14, 1982.

59. Lidwell OM, Lowbury EJ, Whyte W, Blowers R, Stanley SJ, Lowe D. Infection and sepsis after operations for total hip or knee-joint replacement: influence of ultraclean air, prophylactic antibiotics and other factors. *J Hyg Lond* 93:505-529, 1984.
60. Taylor EW. Surgical infection: current concerns. *Eur J Surg Suppl* 5-9, 1997.
61. Lowell JD, Kundsinn RB, Schwartz CM, Pozin D. Ultraviolet radiation and reduction of deep wound infection following hip and knee arthroplasty. *Ann N Y Acad Sci* 353:285-293, 1980.
62. Ostermann PA, Seligson D, Henry SL. Local antibiotic therapy for severe open fractures. A review of 1085 consecutive cases. *J Bone Joint Surg Br* 77:93-97, 1995.
63. Stemberger A, Grimm H, Bader F, Rahn HD, Ascherl R. Local treatment of bone and soft tissue infections with the collagen-gentamicin sponge. *Eur J Surg Suppl* 17-26, 1997.
64. Persson U, Persson M, Malchau H. The economics of preventing revisions in total hip replacement. *Acta Orthop Scand* 70:163-169, 1999.
65. Garvin KL, Evans BG, Salvati EA, Brause BD. Palacos gentamicin for the treatment of deep periprosthetic hip infections. *Clin Orthop* 97-105, 1994.
66. Hill C, Flamant R, Mazas F, Evrard J. Prophylactic cefazolin versus placebo in total hip replacement. Report of a multicentre double-blind randomised trial. *Lancet* 1:795-796, 1981.
67. Southorn PA, Plevak DJ, Wright AJ, Wilson WR. Adverse effects of vancomycin administered in the perioperative period. *Mayo Clin Proc* 61:721-724, 1986.
68. Suter F, Avai A, Fusco U, Gerundini M, Caprioli S, Maggiolo F. Teicoplanin versus cefamandole in the prevention of infection in total hip replacement. *Eur J Clin Microbiol Infect Dis* 13:793-796, 1994.

69. Wall R, Klenerman L, McCullough C, Fyfe I. A comparison of teicoplanin and cefuroxime as prophylaxis for orthopaedic implant surgery: a preliminary report. *J Antimicrob Chemother* 21 Suppl A:141-146, 1988.
70. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin [see comments] [published erratum appears in *J Antimicrob Chemother* 1996 Nov;38(5):919 and 1997 Jul;40(1):147]. *J Antimicrob Chemother* 37:209-222, 1996.
71. Henry SL, Ostermann PA, Seligson D. The prophylactic use of antibiotic impregnated beads in open fractures. *J Trauma* 30:1231-1238, 1990.
72. Ostermann PA, Henry SL, Seligson D. Behandlung von zweit- und drittgradig komplizierten Tibiaschaftfrakturen mit der PMMA-Kettentaschen-Technik.⁷² *Unfallchirurg* 92:523-530, 1989.
73. Wilde AH. Management of infected knee and hip prostheses. *Curr Opin Rheumatol* 5:317-321, 1993.
74. Chapman MW, Mahoney M. The role of early internal fixation in the management of open fractures. *Clin Orthop* 120-131, 1979.
75. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. *J Bone Joint Surg Am* 58:453-458, 1976.
76. Byrd HS, Spicer TE, Cierney G. Management of open tibial fractures. *Plast Reconstr Surg* 76:719-730, 1985.

77. Christensen GD, Simpson WA, Bisno AL, Beachey EH. Experimental foreign body infections in mice challenged with slime-producing *Staphylococcus epidermidis*. *Infect Immun* 40:407-410, 1983.
78. Habash M, Reid G. Microbial biofilms: their development and significance for medical device-related infections. *J Clin Pharmacol* 39:887-898, 1999.
79. Nakamoto DA, Haaga JR, Bove P, Merritt K, Rowland DY. Use of fibrinolytic agents to coat wire implants to decrease infection. An animal model. *Invest Radiol* 30:341-344, 1995.
80. Veenstra GJ, Cremers FF, van Dijk H, Fleer A. Ultrastructural organization and regulation of a biomaterial adhesin of *Staphylococcus epidermidis*. *J Bacteriol* 178:537-541, 1996.
81. van Loosdrecht MC, Norde W, Zehnder AJ. Physical chemical description of bacterial adhesion. *J Biomater Appl* 5:91-106, 1990.
82. Gristina AG, Costerton JW. Bacterial adherence and the glycocalyx and their role in musculoskeletal infection. *Orthop Clin North Am* 15:517-535, 1984.
83. Vaudaux PE, Zulian G, Huggler E, Waldvogel FA. Attachment of *Staphylococcus aureus* to polymethylmethacrylate increases its resistance to phagocytosis in foreign body infection. *Infect Immun* 50:472-477, 1985.
84. Chang CC, Merritt K. Infection at the site of implanted materials with and without preadhered bacteria. *J Orthop Res* 12:526-531, 1994.
85. Dineen P. The effect of suture material in the development of vascular infection. *Vasc Surg* 11:29-33, 1977.
86. Busscher H.J., Weerkamp A.H. Specific and non-specific interactions in bacterial adhesion to solid substrata. *FEMS Microbiology Reviews* 46:165-173, 1987.

87. Patti JM, Allen BL, McGavin MJ, Hook M. MSCRAMM-mediated adherence of microorganisms to host tissues. *Annu Rev Microbiol* 48:585-617, 1994.
88. Vaudaux P et al. Role of host and bacterial factors in modulating staphylococcal adhesion to implanted polymer surfaces. *J Biomater Appl* 5:134-153, 1990.
89. Paulsson M, Kober M, Freij-Larsson C, Stollenwerk M, Wesslen B, Ljungh A. Adhesion of staphylococci to chemically modified and native polymers, and the influence of preadsorbed fibronectin, vitronectin and fibrinogen. *Biomaterials* 14:845-853, 1993.
90. Delmi M, Vaudaux P, Lew DP, Vasey H. Role of fibronectin in staphylococcal adhesion to metallic surfaces used as models of orthopaedic devices. *J Orthop Res* 12:432-438, 1994.
91. Francois P, Vaudaux P, Nurdin N, Mathieu HJ, Descouts P, Lew DP. Physical and biological effects of a surface coating procedure on polyurethane catheters. *Biomaterials* 17:667-678, 1996.
92. Fletcher M. The effects of culture concentration and age, time, and temperature on bacterial attachment to polystyrene. *CAN J MICROBIOL* 23:1-6, 1977.
93. Kjelleberg S, Humphrey B, Marshall KC. Effect of Interfaces on Small, Starved Marine Bacteria. *Appl Environ Microbiol* 43:1166-1172, 1982.
94. Lawrence J.R., Caldwell D.E. Behavior of bacterial stream populations within the hydrodynamic boundary layers of surface microenvironments. *Microbial Ecology* 14:15-27, 1987.
95. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin SH. Microbial biofilms. *Annu Rev Microbiol* 49:711-745, 1995.

96. Skjaerbaek C et al. Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor-binding protein-3 proteolysis. *J Clin Endocrinol Metab* 83:2445-2449, 1998.
97. Beech IB, Gaylarde CC, Smith JJ, Geesey GG. Extracellular polysaccharides from *Desulfovibrio desulfuricans* and *Pseudomonas fluorescens* in the presence of mild and stainless steel. *APPL MICROBIOL BIOTECHNOL* 35:65-71, 1991.
98. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm [see comments]. *Science* 280:295-298, 1998.
99. Van Loosdrecht MCM, Lyklema J, Norde W, Zehnder AJB. Influence of interfaces on microbial activity. *Microbiol Rev* 54:75-87, 1990.
100. Raad I, Darouiche R, Hachem R, Sacilowski M, Bodey GP. Antibiotics and prevention of microbial colonization of catheters. *Antimicrob Agents Chemother* 39:2397-2400, 1995.
101. Reid G, Sharma S, Advikolanu K, Tieszer C, Martin RA, Bruce AW. Effects of ciprofloxacin, norfloxacin, and ofloxacin on in vitro adhesion and survival of *Pseudomonas aeruginosa* AK1 on urinary catheters. *Antimicrob Agents Chemother* 38:1490-1495, 1994.
102. Stewart PS. Theoretical aspects of antibiotic diffusion into microbial biofilms. *Antimicrob Agents Chemother* 40:2517-2522, 1996.
103. Widmer AF, Wiestner A, Frei R, Zimmerli W. Killing of nongrowing and adherent *Escherichia coli* determines drug efficacy in device-related infections. *Antimicrob Agents Chemother* 35:741-746, 1991.

104. Wilson M. Susceptibility of oral bacterial biofilms to antimicrobial agents. *J Med Microbiol* 44:79-87, 1996.
105. Wright TL, Ellen RP, Lacroix JM, Sinnadurai S, Mittelman MW. Effects of metronidazole on *Porphyromonas gingivalis* biofilms. *J Periodontal Res* 32:473-477, 1997.
106. Yassien M, Khardori N, Ahmedy A, Toama M. Modulation of biofilms of *Pseudomonas aeruginosa* by quinolones. *Antimicrob Agents Chemother* 39:2262-2268, 1995.
107. Jansen B, Peters G. Foreign body associated infection. *J Antimicrob Chemother* 32 Suppl A:69-75, 1993.
108. Williams I, Venables WA, Lloyd D, Paul F, Critchley I. The effects of adherence to silicone surfaces on antibiotic susceptibility in *Staphylococcus aureus*. *Microbiology* 143:2407-2413, 1997.
109. Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A. The rate of killing of *Escherichia coli* by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. *J Gen Microbiol* 132:1297-1304, 1986.
110. Jansen B, Schumacher-Perdreau F, Peters G, Pulverer G. New aspects in the pathogenesis and prevention of polymer-associated foreign-body infections caused by coagulase-negative staphylococci. *J Invest Surg* 2:361-380, 1989.
111. Gray ED, Peters G, Verstegen M, Regelmann WE. Effect of extracellular slime substance from *Staphylococcus epidermidis* on the human cellular immune response. *Lancet* 1:365-367, 1984.
112. Johnson GM, Lee DA, Regelmann WE, Gray ED, Peters G, Quie PG. Interference with granulocyte function by *Staphylococcus epidermidis* slime. *Infect Immun* 54:13-20, 1986.

113. Noble MA, Grant SK, Hajen E. Characterization of a neutrophil-inhibitory factor from clinically significant *Staphylococcus epidermidis*. *J Infect Dis* 162:909-913, 1990.
114. Darouiche RO, Farmer J, Chaput C, Mansouri M, Saleh G, Landon GC. Anti-infective efficacy of antiseptic-coated intramedullary nails. *J Bone Joint Surg Am* 80:1336-1340, 1998.
115. Kinner B, Gerstenfeld LC, Einhorn TA, Spector M. Expression of smooth muscle actin in connective tissue cells participating in fracture healing in a murine model. *Bone* 30:738-745, 2002.
116. Emslie KR, Nade S. Acute hematogenous staphylococcal osteomyelitis. A description of the natural history in an avian model. *Am J Pathol* 110:333-345, 1983.
117. Passl R, Muller C, Zielinski CC, Eibl MM. A model of experimental post-traumatic osteomyelitis in guinea pigs. *J Trauma* 24:323-326, 1984.
118. Rissing JP, Buxton TB, Weinstein RS, Shockley RK. Model of experimental chronic osteomyelitis in rats. *Infect Immun* 47:581-586, 1985.
119. Korkusuz F, Uchida A, Shinto Y, Araki N, Inoue K, Ono K. Experimental implant-related osteomyelitis treated by antibiotic-calcium hydroxyapatite ceramic composites. *J Bone Joint Surg Br* 75:111-114, 1993.
120. Laurencin CT et al. Bioerodible polyanhydrides for antibiotic drug delivery: in vivo osteomyelitis treatment in a rat model system. *J Orthop Res* 11:256-262, 1993.
121. Solberg BD, Gutow AP, Baumgaertner MR. Efficacy of gentamycin-impregnated resorbable hydroxyapatite cement in treating osteomyelitis in a rat model. *J Orthop Trauma* 13:102-106, 1999.

122. Littlewood EA, Hattenberger MR, Luscher C, Pataki A, Zak O, O'Reilly T. Local expression of tumor necrosis factor alpha in an experimental model of acute osteomyelitis in rats. *Infect Immun* 65:3438-3443, 1997.
123. An YH, Friedman RJ. Animal models of orthopedic implant infection. *J Invest Surg* 11:139-146, 1998.
124. Norden CW, Keleti E. Experimental osteomyelitis caused by *Pseudomonas aeruginosa*. *J Infect Dis* 141:71-75, 1980.
125. Norden CW. Experimental osteomyelitis. I. A description of the model. *J Infect Dis* 122:410-418, 1970.
126. Rissing JP, Buxton TB, Horner JA, Shockley RK, Fisher JF, Harris R. Synergism between *Bacteroides fragilis* and *Staphylococcus aureus* in experimental tibial osteomyelitis. *J Lab Clin Med* 110:433-438, 1987.
127. Gracia E, Lacleriga A, Monzon M, Leiva J, Oteiza C, Amorena B. Application of a rat osteomyelitis model to compare in vivo and in vitro the antibiotic efficacy against bacteria with high capacity to form biofilms. *J Surg Res* 79:146-153, 1998.
128. Monzon M, Garcia-Alvarez F, Lacleriga A, Amorena B. Evaluation of four experimental osteomyelitis infection models by using precolonized implants and bacterial suspensions. *Acta Orthop Scand* 73:11-19, 2002.
129. Monzon M et al. A simple infection model using pre-colonized implants to reproduce rat chronic *Staphylococcus aureus* osteomyelitis and study antibiotic treatment. *J Orthop Res* 19:820-826, 2001.

130. Hienz SA et al. Development and characterization of a new model of hematogenous osteomyelitis in the rat. *J Infect Dis* 171:1230-1236, 1995.
131. Matsushita K et al. Experimental hematogenous osteomyelitis by *Staphylococcus aureus*. *Clin Orthop* 291-297, 1997.
132. Stroncek DF, Hutton SW, Silvis SE, Vercellotti GM, Jacob HS, Hammerschmidt DE. Sodium morrhuate stimulates granulocytes and damages erythrocytes and endothelial cells: probable mechanism of an adverse reaction during sclerotherapy. *J Lab Clin Med* 106:498-504, 1985.
133. Crane LR, Kapdi CC, Wolfe JN, Silberberg BK, Lerner AM. Xeroradiographic, bacteriologic, and pathologic studies in experimental *staphylococcus* osteomyelitis. *Proc Soc Exp Biol Med* 156:303-314, 1977.
134. Cremieux AC, Carbon C. Experimental models of bone and prosthetic joint infections. *Clin Infect Dis* 25:1295-1302, 1997.
135. Rissing JP. Animal models of osteomyelitis. Knowledge, hypothesis, and speculation. *Infect Dis Clin North Am* 4:377-390, 1990.
136. Rissing JP, Buxton TB, Fisher J, Harris R, Shockley RK. Arachidonic acid facilitates experimental chronic osteomyelitis in rats. *Infect Immun* 49:141-144, 1985.
137. Gerhart TN, Roux RD, Hanff PA, Horowitz GL, Renshaw AA, Hayes WC. Antibiotic-loaded biodegradable bone cement for prophylaxis and treatment of experimental osteomyelitis in rats. *J Orthop Res* 11:250-255, 1993.
138. Dekel S, Lenthall G, Francis MJ. Release of prostaglandins from bone and muscle after tibial fracture. An experimental study in rabbits. *J Bone Joint Surg Br* 63-B:185-189, 1981.

139. Yagmurlu MF, Korkusuz F, Gursel I, Korkusuz P, Ors U, Hasirci V. Sulbactam-cefoperazone polyhydroxybutyrate-co-hydroxyvalerate (PHBV) local antibiotic delivery system: in vivo effectiveness and biocompatibility in the treatment of implant-related experimental osteomyelitis. *J Biomed Mater Res* 46:494-503, 1999.
140. Spagnolo N, Greco F, Rossi A, Ciolli L, Teti A, Posteraro P. Chronic staphylococcal osteomyelitis: a new experimental rat model. *Infect Immun* 61:5225-5230, 1993.
141. Arbes H, Bosch P, Lintner F, Salzer M. First clinical experience with heterologous cancellous bone grafting combined with the fibrin adhesive system (F.A.S.). *Arch Orthop Trauma Surg* 98:183-188, 1981.
142. Greco F, de Palma L, Specchia N, Lisai P. Experimental investigation into reparative osteogenesis with fibrin adhesive. *Arch Orthop Trauma Surg* 107:99-104, 1988.
143. Pfeilschifter J, Laukhuf F, Muller BB, Blum WF, Pfister T, Ziegler R. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone. *J Clin Invest* 96:767-774, 1995.
144. Bauer TW, Schils J. The pathology of total joint arthroplasty. I. Mechanisms of implant fixation. *Skeletal Radiol* 28:423-432, 1999.
145. Sugarman B, Young EJ. Infections associated with prosthetic devices: magnitude of the problem. *Infect Dis Clin North Am* 3:187-198, 1989.
146. Boxma H, Broekhuizen T, Patka P, Oosting H. Randomised controlled trial of single-dose antibiotic prophylaxis in surgical treatment of closed fractures: the Dutch Trauma Trial. *Lancet* 347:1133-1137, 1996.

147. LaMont JT, Sonnenblick EB, Rothman S. Role of clostridial toxin in the pathogenesis of clindamycin colitis in rabbits. *Gastroenterology* 76:356-361, 1979.
148. Littlewood EA, Hattenberger M, Zak O, O'Reilly T. Effect of combination therapy of rifampicin and azithromycin on TNF levels during a rat model of chronic osteomyelitis. *J Antimicrob Chemother* 39:493-498, 1997.
149. Melcher GA et al. Infection after intramedullary nailing: an experimental investigation on rabbits. *Injury* 27 Suppl 3:SC23-SC26, 1996.
150. Klein MP, Rahn BA, Frigg R, Kessler S, Perren SM. Reaming versus non-reaming in medullary nailing: interference with cortical circulation of the canine tibia. *Arch Orthop Trauma Surg* 109:314-316, 1990.
151. Chuard C et al. Resistance of *Staphylococcus aureus* recovered from infected foreign body in vivo to killing by antimicrobials. *J Infect Dis* 163:1369-1373, 1991.
152. Eerenberg JP, Patka P, Haarman HJ, Dwars BJ. A new model for posttraumatic osteomyelitis in rabbits. *J Invest Surg* 7:453-465, 1994.
153. Worlock P, Slack R, Harvey L, Mawhinney R. An experimental model of post-traumatic osteomyelitis in rabbits. *Br J Exp Pathol* 69:235-244, 1988.
154. Schierholz JM BJ. Implant infections: a haven for opportunistic bacteria. *J Hosp Infect* 49:87-93, 2005.
155. Lucke M. Local protection for surgical implants. *Chem Biol* 12:958-959, 2005.
156. Lucke M et al. Gentamicin coating of metallic implants reduces implant related osteomyelitis in rats. *Bone* 32:521-531, 2003.

157. M.Lucke et al. Systemic versus local application of gentamicin in prophylaxis of implant-related osteomyelitis in a rat model. *Bone* 770-778, 5 A.D.